No Data
No Data
EU to Require Additional Cancer Risk Labeling on CAR T Therapies
HK stocks surged | Genscript Bio (01548) rebounded more than 4%, Legend Biotech announced the results of phase 2 study of its treatment for multiple myeloma drugs.
Genscript Bio (01548) rose more than 4% and as of press time, increased by 4.29%, reporting HKD 9.500, turnover of HKD 8997.52 million.
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
These mid-cap stocks were the best performers in the last week. Are they in your portfolio?Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares soared 29.13% in the last week after reporting that its transf
Goldman Cuts 2seventy Bio to Neutral, Cites Competition Concerns
The total relief rate of Xidacilone race reaches 94%, and sales growth is expected.
On June 4th, Genscript Bio (1548.HK, referred to as "Genscript") announced that its subsidiary, Legend Biotech (LEGN.O), released the results of Phase 2 CARTITUDE-2 (Siltuximab) Cohort D study for the treatment of multiple myeloma patients for the first time at the ASCO Annual Meeting.
H.C. Wainwright Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $73
H.C. Wainwright analyst Mitchell Kapoor maintains $Legend Biotech(LEGN.US)$ with a buy rating, and maintains the target price at $73.According to TipRanks data, the analyst has a success rate of 39.2%